
Helena Yu, MD, reviews new first-line data in EGFR exon 20 insertion–mutated NSCLC, from REZILIENT3 and final PAPILLON survival results to oral TKI monotherapy, CNS activity, toxicity management, cost drivers, payer considerations, and how an increasingly crowded treatment landscape may reshape sequencing decisions.





























